Therefore, suppression of the GAP43 functional activity might inhibit both cancer progression and metastasis, and EO is an excellent candidate for the role of both analgesic and cytostatic medicinal substance applied for the treatment of tumor-associated pain syndromes. The gene discussed is GAP43; the disease is cancer.